Elita DeFeo1, Elena Brachtel, Yannick Berker, Nathalie Strittmatter, Julia Hein, Dennis Sgroi, Barbara Smith2, Leo L. Cheng3
1Pathology, Massachusetts General Hospital, Charlestown, MA, United States; 2Surgical Oncology, Massachusetts General Hospital; 3Radiology, Pathology, Massachusetts General Hospital
Diagnosis and prognosis of breast cancer is based on pathological evaluations that have been developed prior to the implementation of imaging based screening. Annual screenings have increased the number of patients with early stages of the disease, challenging the prognostic paradigms. Applying the HRMAS MRS technique, we can quantify individual metabolites from native tissue and correlate those metabolites with quantitative pathology measure from the same samples. In this study we seek to establish breast cancer metabolomic profiles that can improve the accuracy of breast cancer pathological evaluations and the assessment of patient outcome.